688062.SHClinical Trials•prnewswire•
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
Sentiment:Positive (70)
Summary
SHANGHAI, Aug. 19, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the U.S. Food and Drug Administration (FDA). The clearance...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 19, 2025 by prnewswire